



## Press Release

### For further information please contact:

David Brown, Ph.D  
President & Chief Executive Officer  
Cellzome AG  
Meyerhofstr.1  
69117 Heidelberg, Germany  
Tel: +49-6221-137 57-100  
Fax: +49-6221-137 57-201  
press@cellzome.com

### FOR IMMEDIATE RELEASE

## Cellzome Announces Research Collaboration with Johnson & Johnson Pharmaceutical Research and Development

### Heidelberg, Germany, October 28, 2003

Cellzome announced today that it has signed a research collaboration agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica, N.V., Beerse, Belgium. Under the terms of the agreement, which provides for research funding, the companies will collaborate in leveraging Cellzome's drug proteomics platform for clarifying the mechanism of action of compounds in development at J&JPRD.

"We are delighted to be working in collaboration with Johnson and Johnson Pharmaceutical Research and Development," said David Brown, CEO of Cellzome. "Our strategy is to leverage Cellzome's powerful drug proteomics engine through partnerships while building upon our in-house drug discovery capabilities. We are pleased with the momentum in both areas."

Cellzome is a drug discovery company building a R&D pipeline in chronic diseases. Cellzome's drug proteomics platform utilizes both chemical proteomics and pathway expansion. Cellzome takes existing drugs and pharmacologically active compounds to identify their protein targets in the human proteome. These protein targets are then mapped on cellular pathways using Cellzome's pathway expansion technology, detecting the link between the drug, its protein target and the disease pathway. This process allows a detailed molecular understanding of the mode of action of a drug and will be applied in this collaboration.

### About Cellzome AG

Cellzome is a drug discovery company building a R&D pipeline in chronic diseases, with a primary focus on Alzheimer's Disease. Cellzome is

leveraging its powerful drug proteomics engine to generate an ongoing pipeline, both for in-house drug development and through partnership. Cellzome's unique combination of chemical proteomics and pathway expansion enables more efficient and effective drug discovery by focusing on the interface between validated disease pathways, tractable medicinal chemistry and drugable targets.

Cellzome's technology engine allows efficient and scalable chemical proteomics and pathway expansion experiments to be performed in a broad variety of cell types and tissues. A world class mass spectrometry capability guarantees quality controlled, highly sensitive protein identification. Strong, customized IT infrastructure enables efficient sample and data management, coupled with excellent bioinformatics annotation, allows in-depth interpretation in the context of the rapidly growing Cellzome data set.

Founded at the European Molecular Biology Laboratory (EMBL) in May 2000, Cellzome has combined scientific leadership with experienced pharmaceutical management. Under the leadership of President & CEO, Dr. David Brown, Cellzome has moved rapidly into drug discovery. Dr. Brown joined Cellzome in September of 2002, bringing to the company more than 25 years of drug discovery experience. The recent completion of Cellzome's Series C financing round allows the firm to further strengthen and expand its drug discovery and development capabilities.

The company currently has approx. 100 employees with operations in Heidelberg, Germany and London, UK. To learn more about Cellzome visit [www.cellzome.com](http://www.cellzome.com)